The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
This is a Phase III, multicenter, double-masked, randomized, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of KPI-121 1.0% ophthalmic suspension versus placebo in subjects who require treatment of postoperative anterior ocular inflammation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
520
Complete Resolution of Anterior Chamber (AC) Cells at Day 8
Number and percentage of subjects with complete resolution of AC cells in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID. Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better. Anterior Chamber Cells 0 = No cells seen 1. = 1 - 5 cells 2. = 6 - 15 cells 3. = 16 - 30 cells 4. = greater than 30 cells
Time frame: Visit 5 (Day 8) maintained through Visit 6 (Day 15)
Complete Resolution of Ocular Pain at Day 8
Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID. Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes. The following scoring scale was used for ocular pain: 0 = None 1. = Minimal 2. = Mild 3. = Moderate 4. = Moderately Severe 5. = Severe
Time frame: Visit 5 (Day 8) maintained through Visit 6 (Day 15)
Complete Resolution of Ocular Pain at Day 4
Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID. Subjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes. The following scoring scale was used for ocular pain: 0 = None 1. = Minimal 2. = Mild 3. = Moderate 4. = Moderately Severe 5. = Severe
Time frame: Visit 4 (Day 4) maintained through Visit 6 (Day 15)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Eye Center
Chandler, Arizona, United States
Cornea and Cataract Consultants of CA
Phoenix, Arizona, United States
Sall Research Medical Center
Artesia, California, United States
Orange County Ophthalmology
Garden Grove, California, United States
Lugene Eye Institute
Glendale, California, United States
Inland Eye Specialists
Hemet, California, United States
United Medical Research Institute
Inglewood, California, United States
LoBue Laser and Eye Medical Center
Murrieta, California, United States
Pendleton Eye Center
Oceanside, California, United States
North Bay Eye Associates, Inc.
Petaluma, California, United States
...and 25 more locations
Complete Resolution of Anterior Chamber (AC) Flare at Day 4
Number and percentage of subjects with complete resolution of AC flare in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID. Investigators were asked to grade AC flare based on the following scale wherein higher scores indicate a higher degree of flare present and a decrease across time indicates the condition is getting better. Anterior Chamber Flare 0 = None 1. = Mild (trace to clearly noticeable, visible) 2. = Moderate (without plastic aqueous humor) 3. = Marked (with plastic aqueous humor) 4. = Severe (with fibrin deposits and/or clots)
Time frame: Visit 4 (Day 4) maintained through Visit 6 (Day 15)
Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 4
The difference in mean changes from BL in AC cell count grade at Day 4 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID. Investigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better. Anterior Chamber Cells 0 = No cells seen 1. = 1 - 5 cells 2. = 6 - 15 cells 3. = 16 - 30 cells 4. = greater than 30 cells
Time frame: Visit 1 (Baseline) and Visit 4 (Day 4)